BridgeMD
Tests treatment safety and results for Solid Tumor
Official title A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
ClinicalTrials.gov ID: NCT07107633
What this study is testing
What is Technetium [99mTc]-H7ND injection?
Technetium [99mTc]-H7ND injection is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main purpose of this study is to evaluate the effectiveness of technetium [99mTc]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium [99mTc]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Only those who meet all the following requirements are eligible to join the group:
- Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;
- people with gastrointestinal malignant tumor confirmed by histology/cytology;
- people to be surgically removed or explored;
- The estimated survival time is ≥12 weeks;
See the full eligibility criteria
- Only those who meet all the following requirements are eligible to join the group:
- Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;
- people with gastrointestinal malignant tumor confirmed by histology/cytology;
- people to be surgically removed or explored;
- The estimated survival time is ≥12 weeks;
- people of childbearing age agreed to adopt effective contraceptive measures during the study period;
- people fully understand the purpose, nature, methods and possible adverse reactions of the experiment, voluntarily participate in and sign a written informed consent, and are willing to follow the requirements of the...
- According to the researcher's judgment, during the screening period, from the imaging examination to the comprehensive real diagnosis information result, the patients were treated with anti-digestive tract tumor;
- symptomatic brain metastases who need treatment;
- Have serious cardiovascular and cerebrovascular diseases;
- There are other contraindications for imaging examination of the research plan, such as claustrophobia;
- Have a history of other malignant tumors;
- Pregnant (pregnancy test positive in screening period) or lactating women;
- Other circumstances that the researcher considers inappropriate to participate in this clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.